ライフサイエンスコーパス: bone scintigraphy

1 T/CT and whole-body MRI were performed after bone scintigraphy.

2 ntitative expression of tumor burden seen on bone scintigraphy.

3 the referring physician and did not undergo bone scintigraphy.

4 oms with focal abnormalities on conventional bone scintigraphy.

5 iography, computed tomographic scanning, and bone scintigraphy.

6 ase bone scintigraphy and combined leukocyte/bone scintigraphy.

7 x of the patients also underwent three-phase bone scintigraphy.

8 %, respectively, compared to 91% and 55% for bone scintigraphy.

9 esulted in unusually extensive photopenia on bone scintigraphy.

10 %, respectively, compared to 88% and 77% for bone scintigraphy.

11 for radiographic skeletal survey compared to bone scintigraphy.

12 phosphono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy.

13 red with a combination of whole-body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs.

14 %, P < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs.

15 of bone metabolism is dominated by gamma-ray bone scintigraphy: a technique in which gamma-ray emissi

16 Bone scintigraphy accurately diagnoses osteomyelitis in

17 metastases were studied with both 99mTC MDP bone scintigraphy and 18FDG PET, and the number of lesio

18 Results of bone scintigraphy and biochemical investigations were an

19 his series, was superior to both three-phase bone scintigraphy and combined leukocyte/bone scintigrap

20 on models including the visual assessment of bone scintigraphy and other relevant covariates.

21 The annual use of bone scintigraphy and radiotracer therapies was unchange

22 rade 2 or 3 myocardial radiotracer uptake on bone scintigraphy and the absence of a monoclonal protei

23 pared the results with those for (99m)Tc-MDP bone scintigraphy and whole-body MRI.

24 ety of these patients underwent radionuclide bone scintigraphy, and 70 patients underwent brain CT or

25 , chest computed tomography scan, liver MRI, bone scintigraphy, and axial skeleton MRI have been prov

26 T findings were correlated with those of CT, bone scintigraphy, and biopsy.

27 body PET was more accurate than thoracic CT, bone scintigraphy, and brain CT or MR imaging in staging

28 Computed tomography, bone scintigraphy, and lumbar spine x-rays were performe

29 severity as measured by both radiograph and bone scintigraphy, and synovial fluid IL-1beta was assoc

30 Four underwent bone scintigraphy, and two underwent gallium scintigraph

31 indicator and support further exploration of bone scintigraphy as an imaging biomarker in CRMPC.

32 ming various imaging examinations, including bone scintigraphy as well as CT and MRI of the lumbosacr

33 All had negative conventional CT and bone scintigraphy before enrollment.

34 ative assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients wh

35 rates of overuse defined as combined use of bone scintigraphy (BS) and PET, which current guidelines

36 tomography/computed tomography (PET/CT) and bone scintigraphy (BSc) in women with suspected MBC.

37 dred consecutive young athletes referred for bone scintigraphy by a sports medicine clinic because of

38 f metaphyseal osteomyelitis in a child where bone scintigraphy demonstrated photopenia of the distal

39 cinoma of the gall bladder is rare and hence bone scintigraphy does not form a part of the routine wo

40 MR alone and CT and MR combined with bone scintigraphy enable the accurate detection of stage

41 Bone scintigraphy enables the diagnosis of cardiac ATTR

42 tic resonance [MR] imaging, radiography, and bone scintigraphy) findings in three adolescent boys wit

43 isease, replace technetium-99m diphosphonate bone scintigraphy for osteomedullary metastasis assessme

44 treotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PG

45 that of a combination of whole-body MRI and bone scintigraphy in patients with breast and prostate c

46 We have compared 18FDG PET with 99mTc MDP bone scintigraphy in patients with skeletal metastases f

47 18FDG PET is superior to bone scintigraphy in the detection of osteolytic breast

48 taken with the aim of evaluating the role of bone scintigraphy in the diagnosis and staging of LCH.

49 predictive value but is less sensitive than bone scintigraphy in the identification of osseous metas

50 r study to ascertain the diagnostic value of bone scintigraphy in this disease.

51 y, supporting the hypothesis that whole-body bone scintigraphy is a means of quantifying the total-bo

52 chnetium methylene diphosphonate (99mTc MDP) bone scintigraphy is currently the method of choice for

53 Bone scintigraphy may have a role in monitoring a patien

54 aphy (n = 26), computed tomography (n = 12), bone scintigraphy (n = 15), and magnetic resonance (MR)

55 aphics and images from radiography (n = 36), bone scintigraphy (n = 17), angiography (n = 4), compute

56 If neither conventional bone scintigraphy nor NaF PET were available, referring

57 nventional CT, appropriately supplemented by bone scintigraphy or other modalities), was defined pros

58 s to patients with findings confirmed by CT, bone scintigraphy, or biopsy or considered highly likely

59 yethylene-diphosphonate ((99m)Tc-HDP) planar bone scintigraphy (pBS), (99m)Tc-HDP SPECT/CT, (18)F-NaF

60 Bone scintigraphy receiver operating characteristic curv

61 Bone scintigraphy remains the most commonly used imaging

62 Bone scintigraphy remains the standard, but the specific

63 o-phase (soft-tissue and delayed) whole-body bone scintigraphy results in appropriate diagnosis and t

64 Bone scintigraphy studies were reviewed and graded accor

65 Radiographic skeletal surveys and whole-body bone scintigraphy study results were reviewed for all pa

66 disease severity as determined by late-phase bone scintigraphy, supporting the hypothesis that whole-

67 long been recognized that technetium-labeled bone scintigraphy tracers can localize to myocardial amy

68 resonance imaging and cardiac repurposing of bone scintigraphy tracers.

69 Bone scintigraphy using (99m)Tc-labeled methylene diphos

70 myopathies, myocardial radiotracer uptake on bone scintigraphy was >99% sensitive and 86% specific fo

71 2014 and October 2015 and for whom baseline bone scintigraphy was available.

72 Three-phase bone scintigraphy was positive in all six neuropathic jo

73 Bone scintigraphy was sensitive (1.0) but nonspecific (0

74 ng to our pediatric radiology department for bone scintigraphy were evaluated.

75 Findings at bone scintigraphy were positive in all lesions.

76 ostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this st

77 and therapeutic radiopharmaceutical use and bone scintigraphy were unchanged.

78 CT, MR, and bone scintigraphy were used to evaluate tumor stage.

79 ith unexplained hypercalcemia who under went bone scintigraphy, which demonstrated marked tracer upta

80 he results were also compared with available bone scintigraphy, white blood cell scintigraphy, and (1

81 Bone scintigraphy with SPECT can help identify patients

82 Group A patients underwent bone scintigraphy with SPECT prior to injection.

83 If NaF PET were unavailable, conventional bone scintigraphy would have been ordered in 85% of pati